Search clinical trials for: Tislelizumab plus Fruquintinib and SBRT

Total 4639 results

Huazhong University of Science and Technology

Active, not recruiting

Tislelizumab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With Advanced CRC

Patients With Advanced Metastatic Colorectal Cancer

China
Sun Yat-sen University

Not yet recruiting

Fruquintinib Plus PD-1 Antibody in pMMR / MSS Locally Advanced Rectal Cancer (LARC) With High Immune Score

Locally Advanced Rectal Cancer

China
Peking University Cancer Hospital & Institute

Recruiting

Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC

Unresectable Hepatocellular Carcinoma | Oligometastatic Disease

China
Huazhong University of Science and Technology

Recruiting

Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC

Colorectal Cancer

China
Sun Yat-sen University
Hutchmed; BeiGene

Not yet recruiting

Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer

Metastatic Colorectal Cancer | mCRC

China
Fudan University

Recruiting

WBRT With Hippocampal-avoidance Technique Followed by SRT for Extensive-stage SCLC With Baseline Brain Metastases

Brain Metastases | SCLC,Extensive Stage

China
Fudan University

Recruiting

The Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE)

Metastatic Colorectal Cancer

China
Wuhan Union Hospital, China

Not yet recruiting

SBRT Combined With Fruquintinib Plus PD-1/CTLA-4 Antibody for Third-line Treatment in mCRC

Metastatic Colorectal Cancer

China
Sun Yat-sen University

Recruiting

Fruquintinib Combined With TAS-102 in the Treatment of Patients With Advanced Metastatic CRC

Metastatic Colorectal Cancer

China
Fudan University

Not yet recruiting

Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer

Colorectal Cancer

China
Fujian Cancer Hospital

Not yet recruiting

A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver Metastases

Colo-rectal Cancer
BeiGene

Completed

A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) or Gastric/Gastroesophageal Junction Cancer (GC/GEJC)

Carcinoma, Hepatocellular | Gastric/Gastroesophageal Junction Cancer

China
BeiGene
Hutchison Medipharma Limited

Completed

Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors

Advanced Solid Tumors

Korea, Republic of, China
Becky Marquez

Recruiting

Family Functioning in Obesity Treatment for Mexican Americans

Obesity

United States
Jing-yuan Fang, MD, Ph. D

Recruiting

Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial

Colorectal Cancer

China
Fudan University

Recruiting

Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC

HER2-positive Gastric Cancer | Immunotherapy

China
Hutchison Medipharma Limited
BeiGene

Active, not recruiting

A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors

Colorectal Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Solid Tumor, Unspecified, Adult

United States
Peking Union Medical College Hospital

Not yet recruiting

Nimotuzumab Plus Tislelizumab for Recurrent and Metastatic Cervical Cancer

Cervical Cancer
Cancer Institute and Hospital, Chinese Academy...

Recruiting

FMT Combined With Immune Checkpoint Inhibitor and TKI in the Treatment of CRC Patients With Advanced Stage

Colorectal Neoplasms Malignant

China
Juravinski Cancer Center
Hamilton Health Sciences Corporation; Juravinski Cancer Centre Foundation

Unknown

Stereotactic Body Radiotherapy Boost After Palliative Radiotherapy for Spinal Cord Compression (CRUSSH)

Spinal Cord Compression | Cauda Equina Syndrome | Stereotactic Body Radiotherapy

Canada
West China Hospital

Recruiting

Neoadjuvant Therapy for Locally Advanced Rectal Cancer With Fruquintinib, Toripalimab and SRT

Rectal Cancer

China
Sun Yat-sen University

Recruiting

Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgery

Immunotherapy | DMMR Colorectal Cancer | Anti PD-1

China
Nanfang Hospital, Southern Medical University

Recruiting

Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore

Gastric Cancer

China
Lei Li

Recruiting

Tislelizumab and Radiotherapy for Recurrent Cervical Cancer

Recurrent Cervical Carcinoma | Radiotherapy | Immunotherapy | Survival Outcomes | Immune Checkpoint Inhibitors | Objective Response Rate | Metastatic Cervical Carcinoma | Tislelizumab | Persistent Cervical Carcinoma | Anti-programmed Cell Death Receptor 1

China
Sun Yat-sen University

Active, not recruiting

SBRT Followed by Neoadjuvant Immunochemotherapy in Resectable Stage II to III Non-small Cell Lung Cancer (SACTION01)

Carcinoma, Non-Small-Cell Lung

China
IRCCS Azienda Ospedaliero-Universitaria di Bologna

Unknown

Improving REsectability in Pancreatic NEoplasms (IRENE) (IRENE)

Pancreatic Cancer | Stereotactic Body Radiotherapy

Italy
Fudan University

Not yet recruiting

Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients

Colorectal Cancer | Microsatellite Stable Colorectal Carcinoma

China
Zhongshan People's Hospital, Guangdong, China

Recruiting

Anrotinib and Tirelizumab in First-line Treatment of RM-NPC

Nasopharyngeal Carcinoma

China
Peking University

Recruiting

Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment

Liver Metastasis Colon Cancer | MSS | ctDNA Genotype | Failed From Standard Treatment

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

An Phase III Study, Multicenter，Randomized Controlled Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.

Bladder Cancer

China
Guangxi Medical University

Not yet recruiting

Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation (PREVENT-2)

Recurrence | Hepatocellular Carcinoma | Immune Checkpoint Inhibitor

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

TILA-TACE in Treatment of Hepatocellular Carcinoma

Overall Survival | Tumor Response Rate

China
Royal Marsden NHS Foundation Trust
University College, London; The Leeds Teaching Hospitals NHS Trust; Belfast Health... and other collaborators

Unknown

Targeted Radiotherapy in Androgen-suppressed Prostate Cancer Patients. (TRAP)

Prostate Cancer | Metastasis | Toxicity Due to Radiotherapy | Circulating Tumour DNA

United Kingdom
Fudan University

Not yet recruiting

Fruquintinib Plus Capecitabine Versus Capecitabine as Maintenance Therapy for Metastatic Colorectal Cancer After First-line Chemotherapy

Colorectal Cancer | Colorectal Cancer Stage IV
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Fruquintinib Plus Capecitabine as Maintenance Treatment of RAS / BRAF Wild-type Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Hutchison Medipharma Limited

Completed

Fruquintinib Food Effect and Proton Pump Inhibitor Study

Food-drug Interaction | Drug Interaction

United States
Beijing Friendship Hospital

Recruiting

A Phase II Study of Fruquintinib Combined With Capecitabine as First-line Treatment for Advanced Metastatic Colorectal Cancer Unsuitable for Intravenous Chemotherapy

Unresectable Metastatic Colorectal Cancer

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer

Unresectable/Metastatic Colorectal Cancer

China
AIPING ZHOU

Unknown

Phase II Trial of Fruquintinib With Sintilimab in Treating Selected Refractory Metastatic Colorectal Cancer Patients

Colorectal Cancer

China
Pharmacyclics LLC.

Completed

Radiation Therapy Plus Gadolinium Texaphyrin in Treating Patients With Brain Metastases

Metastatic Cancer

United States, Canada
Betta Pharmaceuticals Co., Ltd.

Unknown

Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain Metastases

Non-small-cell Lung Cancer

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Fruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer

Colorectal Neoplasm

China
Jiangsu Cancer Institute & Hospital

Active, not recruiting

Neoadjuvant Chemo-hypoRT Plus PD-1 Antibody (Tislelizumab) in Resectable LA-G/GEJ (RARE)

Gastric or Gastroesophageal Junction Adenocarcinoma

China
Peking University People's Hospital

Completed

Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' Resistance

Soft Tissue Sarcoma | Bone Sarcoma | Refractory Tumor

China
Zhejiang Cancer Hospital

Not yet recruiting

Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC

Metastatic Colorectal Cancer | Metastatic Colorectal Adenocarcinoma | CRC

China
Henan Provincial People's Hospital

Not yet recruiting

Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma

Recurrent Glioblastoma

China
Sun Yat-sen University

Recruiting

Efficacy of Modified Fruquintinib in Colorectal Cancer Liver Metastases: A Phase II Study

Colorectal Cancer Metastatic

China
Junjie Peng

Not yet recruiting

A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-isolated Hepatic Metastatic Colorectal Cancer: a Single-center, Phase 2 Study

Colorectal Cancer

China
Peking Union Medical College Hospital

Recruiting

Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC

Hepatocellular Carcinoma

China
University Hospital, Bonn
Mundipharma Research GmbH & Co KG

Terminated

A Clinical Trial to Assess the Safety & Efficacy of the Treatment of Patients With Metastasis From Malignant Melanoma - Treatment Consists of the Substances Lomustine (Capsules) & Cytarabine (Injected Into an Area Near the Spinal Cord), Accompanied by Radiotherapy of the Brain

Leptomeningeal Metastasis From Malignant Melanoma

Germany

3

Subscribe